Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.37 |
| ▸ | REN | P00797 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PEPD | P12955 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8259429 | 1.00 | ACE (0.37) | ACERENKDM4EF2LMNA | |
| SCHEMBL12205476 | 1.00 | ACE (0.37) | ACERENKDM4EF2LMNA | |
| SCHEMBL3392656 | 0.94 | EPHX1 (0.39) | ACERENKDM4EPARP1EPHX1 | |
| SCHEMBL18574581 | 0.88 | EPHX1 (0.36) | PARP1EPHX1DPP4FAPDPP7 | |
| SCHEMBL17083297 | 0.88 | EPHX1 (0.36) | PARP1EPHX1DPP4FAPDPP7 | |
| SCHEMBL17427852 | 0.88 | EPHX1 (0.36) | PARP1EPHX1DPP4FAPDPP7 | |
| SCHEMBL23057742 | 0.86 | ACE (0.40) | ACERENKDM4EF2LMNA | |
| SCHEMBL19488378 | 0.85 | ACE (0.38) | ACERENKDM4EF2LMNA | |
| SCHEMBL10692929 | 0.85 | L3MBTL1 (0.35) | ACERENKDM4EF2LMNA | |
| SCHEMBL16000536 | 0.82 | ACE (0.38) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-11141406-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2021-10-12 | — | — | US | disclosed |
| US-11078189-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2021-08-03 | — | — | US | disclosed |
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200316030-A1 | PHARMACEUTICAL COMPOUNDS | SILICON VALLEY BANK | 2020-10-08 | — | — | US | disclosed |
| US-10730866-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200172515-A1 | PHARMACEUTICAL COMPOUNDS | SILICON VALLEY BANK | 2020-06-04 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10005768-B2 | Carboxamide derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-06-26 | — | — | US | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-0253785-A1 | Efficient stereoconservative syntheses of 1-substituted (S)- and (R)-2-aminomethylpyrrolidines and intermediates therein | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | CACNA1A, TRPV1, TRPA1 | ACE 965/4885REN 385/4885KDM4E 2252/4885 |
| US-11141406-B2 | Pharmaceutical compounds | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | ACE 1807/4885REN 337/4885KDM4E 3963/4885 |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | ACE 296/4885REN 265/4885KDM4E 2106/4885 |
| US-10005768-B2 | Carboxamide derivatives and use thereof | TRPV1, CACNA1A, SCN10A | ACE 1646/4885REN 323/4885KDM4E 1185/4885 |
| US-20200316030-A1 | PHARMACEUTICAL COMPOUNDS | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | ACE 1795/4885REN 310/4885KDM4E 3912/4885 |
| US-20200407338-A1 | ISOQUINOLINE DERIVATIVES AND USE THEREOF | KCNQ3, KCNQ5, KCNQ4 | ACE 1764/4885REN 140/4885KDM4E 1788/4885 |
| US-11078189-B2 | Pharmaceutical compounds | HRH4, CHRM5, CHRM1 | ACE 1053/4885REN 137/4885KDM4E 1795/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | ACE 623/4885REN 409/4885KDM4E 1822/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | ACE 485/4885REN 2518/4885KDM4E 4338/4885 |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFRKB, NFKB1 | ACE 1593/4885REN 1096/4885KDM4E 1666/4885 |
| US-10730866-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | ACE 2457/4885REN 199/4885KDM4E 206/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | ACE 29/4885REN 131/4885KDM4E 3117/4885 |
| US-20200172515-A1 | PHARMACEUTICAL COMPOUNDS | HRH4, CHRM5, CHRM1 | ACE 1053/4885REN 137/4885KDM4E 1795/4885 |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | ACE 4595/4885REN 3326/4885KDM4E 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.